# Pizarra — PT-pseudo_180352970ace (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_180352970ace
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 3.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.116 ng/mL²
  - PSA velocity: 1.18 ng/mL/yr
  - Prior PSA: 2.8 ng/mL
  - Prostate volume: 31.97 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7869916 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.7 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 32 mL. csPCa 0.79.

Vitals: weight 71 kg, height 183 cm, BMI 21.2, BP 124/82 mmHg, HR 84 bpm. Smoking: Non-smoker.

Chief complaint: Clinical concern stems from a sustained increase in prostate-specific antigen levels coupled with a newly identified high-risk lesion on multiparametric magnetic resonance imaging.

History: At sixty-three years of age, this self-employed carpentry contractor presents with a minimal International Prostate Symptom Score of 5/35, despite an initial workup for hesitancy and frequency two years prior. Prior biopsy bucket: None. He has never wed and resides with his partner, while his grown daughter acts as the designated emergency contact. A strict non-smoker, his daily routine features biweekly tennis matches and a weekly alcohol intake hovering around fourteen units. Medical background remains entirely clear, with no comorbidities or active prescriptions. He denies haematuria, skeletal discomfort, or unaccounted weight reduction, and has arranged for an Arabic interpreter to facilitate his next consultation.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The gland exhibits no focal irregularities, aligning with a benign digital assessment. Hemodynamic parameters show a blood pressure of 124/82 mmHg and a pulse of 84 beats per minute. Systemic evaluation notes a well-built individual in comfortable repose, featuring unremarkable pulmonary fields and a steady cardiac rhythm upon auscultation.

Patient info: self-employed contractor (carpentry); Never married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 14 units / week; exercise Tennis 2x/week; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.87 +/- 0.12   (95% CI 0.57-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.06  (few labelled cases resemble this one)
  - 8.2 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=3.7, age=63.0, psad=0.116, dre_ord=0.0, vol=31.97, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.18 ng/mL/yr) against the PI-RADS 5 score, which is a critical dynamic factor. It also could not incorporate the full context from the retrieved documents, specifically the PSA history trend and the laboratory panel, which might indicate a more aggressive trajectory than the single PSA value suggests. Finally, the prior did not account for the clinical context provided in the notes, such as the mild IPSS score (5/35) and the DRE being 'Normal', which might temper the urgency suggested by the high PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a high probability of biopsy (0.87). A failure mode is that the PI-RADS 5 score might be an over-indicator when combined with a normal DRE and a low IPSS score, suggesting the lesion is indolent. Another failure mode is the wide error bar ($\pm 0.12$) and the epistemic uncertainty ($\pm 0.06$), meaning the prior is highly sensitive to the specific context missing. A third failure mode is the lack of information on the PSA trend; if the PSA velocity is misleading or if the prior PSA (2.8) was significantly lower than the current 3.7, the trajectory might be less concerning than the prior model assumes.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <What is the full lab panel, especially other markers?> -> <If markers suggest high risk, it would increase the need for biopsy.>
  <PSA history (trend)> -> <What is the full PSA trajectory beyond the headline value?> -> <A rapidly rising trend would strongly argue for biopsy.>
  <radiology / mpMRI report> -> <What is the full mpMRI prose?> -> <Detailed description of the lesion characteristics could modify the PI-RADS 5 interpretation.>
  <previous GP / urology consultation notes> -> <What were the findings or concerns from prior notes?> -> <Prior concerns or previous workup results could contextualize the current findings.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units and dates. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  Subject: Prostate Multiparametric MRI | Institution: Catharina Ziekenhuis, Eindhoven | Date: 15 January 2025

  Clinical Indication:
  Clinically indicated due to a rising prostate-specific antigen level of 3.7 ng/mL, prompting comprehensive imaging.

  FINDINGS:
  Glandular dimensions measure 31.97 mL. A discrete 12 mm focus of hypointensity occupies the right mid peripheral zone on T2-weighted sequences. Diffusion-weighted imaging shows pronounced signal restriction, mirrored by corresponding ADC hypointensity. Post-contrast phases capture early, localized enhancement within this region. Extracapsular extension, seminal vesicle involvement, nodal enlargement, and skeletal metastases are absent.

  IMPRESSION:
  PI-RADS 5 lesion in the right mid peripheral zone. Prostate volume 31.97 mL. PSA density 0.116 ng/mL/mL. csPCa predicted probability 0.7869916.

  **PSA history**
  {"case_id": "PT-pseudo_180352970ace", "psa_trend": [{"date": "Oct 2022", "val": 1.6}, {"date": "Jul 2023", "val": 2.1}, {"date": "Apr 2024", "val": 2.8}, {"date": "Jan 2025", "val": 3.7}]}

  **laboratory results**
  {"case_id": "PT-pseudo_180352970ace", "laboratory_results": [{"name": "PSA", "val": "3.7 ng/mL", "date": "13 Dec 2024", "flag": ""}, {"name": "Free PSA", "val": "0.62 ng/mL", "date": "13 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "17%", "date": "13 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "13.7 g/dL", "date": "13 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.7 x10^9/L", "date": "13 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "251 x10^9/L", "date": "13 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "89 umol/L", "date": "13 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "13 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "11.9 nmol/L", "date": "13 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "42 U/L", "date": "13 Dec 2024", "flag": ""}, {"name": "LDH", "val": "127 U/L", "date": "13 Dec 2024", "flag": ""}]}

  **previous GP / urology consultation notes**
  {"date": "24 Jan 2024", "author": "Dr. K. Bakker (GP)", "text": "During a standard check-in, laboratory results placed the prostate-specific antigen at 2.8 ng/mL, highlighting a consistent climb from earlier values. No bothersome voiding complaints or constitutional symptoms were noted. Urology consultation was arranged to investigate the upward trend."}, {"date": "29 Jan 2023", "author": "Dr. K. Bakker (GP)", "text": "A scheduled assessment noted a prostate-specific antigen reading of 1.8 ng/mL, edging past prior reference points. Occasional daytime urinary frequency was reported, though obstructive features remained absent."}

NOT RETRIEVED
  get_family_history: Not called because the retrieval of other documents provided sufficient context regarding the clinical picture.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the right mid peripheral zone
  PSA velocity of 1.18 ng/mL/yr (from current to prior)
  PSA trend shows a consistent rise from 1.6 ng/mL (Oct 2022) to 3.7 ng/mL (Jan 2025)
  csPCa predicted probability of 0.7869916

  AGAINST sampling this patient now:
  DRE findings: Normal
  IPSS score: 5/35 (mild LUTS)
  Prostate volume: 31.97 mL

WHERE THIS LEANS
  The evidence strongly argues for sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity/trend, which contradicts the benign DRE and low IPSS score. This leans toward the statistical prior but with stronger clinical justification.

[Sections actually revealed in this consultation: psa_trend, laboratory_results, radiology_report, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging and concerning biochemical data. The PI-RADS 5 lesion in the right mid peripheral zone is a decisive factor, strongly supported by the rising PSA trend from 1.6 ng/mL to 3.7 ng/mL, which overrides the benign DRE and low IPSS score. The combination of PI-RADS 5 and the PSA velocity of 1.18 ng/mL/yr provides strong clinical justification for sampling.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: psa_trend, laboratory_results, radiology_report, previous_notes
